Literature DB >> 8468583

Functional imaging in relation to parkinsonian syndromes.

D J Brooks1.   

Abstract

Parkinsonism is a feature not only of Parkinson's disease but also of many other diseases affecting basal ganglia function. Functional imaging (PET and SPECT) can demonstrate the various resting patterns of disruption of regional cerebral blood flow, metabolism, and neuropharmacology associated with different parkinsonian disorders. 18F-dopa PET also has the potential to detect subclinical dysfunction of dopaminergic terminals in at-risk subjects. Finally, functional imaging can help us understand the nature of the networks involved in performing different motor tasks, and can reveal how these networks malfunction in the presence of bradykinesia or parkinsonian tremor.

Entities:  

Mesh:

Year:  1993        PMID: 8468583     DOI: 10.1016/0022-510x(93)90061-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  17 in total

1.  Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.

Authors:  J O Rinne; H Ruottinen; J Bergman; M Haaparanta; P Sonninen; O Solin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

2.  Neuropsychological, psychiatric, and cerebral perfusion correlates of leukoaraiosis in Alzheimer's disease.

Authors:  S E Starkstein; L Sabe; S Vázquez; G Di Lorenzo; A Martínez; G Petracca; A Tesón; E Chemerinski; R Leiguarda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

3.  Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease.

Authors:  Ruth Djaldetti; Therese A Treves; Ilan Ziv; Eldad Melamed; Yair Lampl; Mordechai Lorberboym
Journal:  Neurol Sci       Date:  2009-06-05       Impact factor: 3.307

4.  [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

Authors:  J Booij; G Tissingh; G J Boer; J D Speelman; J C Stoof; A G Janssen; E C Wolters; E A van Royen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

5.  Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography.

Authors:  Z Walker; D C Costa; A G Janssen; R W Walker; G Livingstone; C L Katona
Journal:  Eur J Nucl Med       Date:  1997-06

Review 6.  Single-photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson's disease.

Authors:  R B Innis
Journal:  Eur J Nucl Med       Date:  1994-01

7.  Brain glucose utilisation in a patient with "athymhormia" from a family with autosomal dominant parkinsonism and psychic disturbances.

Authors:  F Le Doze; J C Baron; R M Marie; F Eustache; B Lechevalier; C Schupp; J M Travere; M C Petit-Taboue
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

Review 8.  PET Imaging in Movement Disorders.

Authors:  Baijayanta Maiti; Joel S Perlmutter
Journal:  Semin Nucl Med       Date:  2018-08-16       Impact factor: 4.446

9.  Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging.

Authors:  Soyoung Jin; Minyoung Oh; Seung Jun Oh; Jungsu S Oh; Sang Ju Lee; Sun Ju Chung; Chong Sik Lee; Jae Seung Kim
Journal:  Nucl Med Mol Imaging       Date:  2012-11-03

10.  Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson's disease.

Authors:  Wen-Sheng Huang; Meei-Shyuan Lee; Jiann-Chyun Lin; Cheng-Yu Chen; Yu-Wen Yang; Shinn-Zong Lin; Shiaw-Pyng Wey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.